Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 March 2024
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirikizumab for treating moderately to severely active Crohn's disease ID6244Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC